StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)

StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report released on Wednesday morning. The firm issued a sell rating on the stock.

Other analysts have also issued research reports about the stock. Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Price Performance

NASDAQ:SYRS opened at $0.09 on Wednesday. The firm has a market capitalization of $2.31 million, a P/E ratio of -0.03 and a beta of 1.29. Syros Pharmaceuticals has a 1-year low of $0.07 and a 1-year high of $7.27. The company’s fifty day moving average price is $0.19 and its 200-day moving average price is $0.98.

Institutional Trading of Syros Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Two Sigma Securities LLC acquired a new stake in Syros Pharmaceuticals during the fourth quarter valued at $25,000. GSA Capital Partners LLP acquired a new stake in shares of Syros Pharmaceuticals in the third quarter valued at about $34,000. Finally, Exome Asset Management LLC grew its position in shares of Syros Pharmaceuticals by 87.6% in the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after purchasing an additional 139,400 shares during the period. Institutional investors and hedge funds own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.